Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: NeuroOne Moves Forward With Brain Electrode 510(k) Submission

Executive Summary

The company has submitted a 510(k) request for its OneRF Ablation System, which will repurpose previously implanted electrodes into a tool for brain tissue removal.

You may also be interested in...



News We’re Watching: Activist Investor Causes Kerfuffle At Nevro, Lifespin Launches Antibiotic Dx, And More

Medtech Insight's News We're Watching highlights medtech industry news developments that you may have missed over the last few weeks. Last week, EndoQuest closed a $42m round to support its endoluminal surgery system, Intuitive Ventures closed a $150m round, Noah Surgical announced the first biopsy procedures with its Galaxy technology in Asia, the FDA cleared Smileyscope's VR system to reduce needle anxiety, and Guardant will collaborate with Cancer Research UK.

NeuroOne’s CEO Talks About 510(k) Clearance Of Evo sEEG Electrodes

Medtech Insight spoke to Dave Rosa, CEO of NeuroOne, about working with the FDA to get a 510(k) clearance.

NeuroOne: Thinner Is Better When It Comes To Brain Electrodes

NeuroOne manufactures the thinnest FDA-approved stereoelectroencephalography electrode for 30-day use, and a recent Emory University study could further expand their applications.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel